Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine and Spironolactone in Dialysis-dependent ESRD
NCT01855334Phase 4Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2013
- Primary completion
- Jul 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone, arginine in cardiovascular disease (CVD), sponsored by Brigham and Women's Hospital. Planned start Sep 2013; status: withdrawn.
02
Drugs
spironolactonearginine
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT01855334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01855334.